TXNDC5 Governs Extracellular Matrix Homeostasis in Pulmonary Hypertension

This study identifies TXNDC5 as a critical driver of pulmonary hypertension by mediating hypoxia-induced extracellular matrix remodeling via biglycan in endothelial cells, thereby establishing it as a promising therapeutic target for the disease.

The Gist

The Big Picture: A Traffic Jam in the Lungs

Imagine your lungs are a bustling city with millions of tiny roads (blood vessels) carrying oxygen to your heart. In a healthy city, these roads are smooth, wide, and flexible.

Pulmonary Hypertension (PH) is like a massive construction project gone wrong. The walls of these tiny roads get thick, stiff, and clogged. The "traffic" (blood) can't flow easily, so the pressure builds up. Eventually, the heart (the city's main pump) has to work so hard to push blood through these clogged roads that it starts to fail. Currently, doctors can treat the symptoms, but they can't fix the clogged roads or reverse the damage.

This paper discovers a specific "foreman" inside the cells lining these roads who is accidentally ordering too much construction, causing the traffic jam.

---

The Culprit: TXNDC5 (The Overzealous Foreman)

The researchers found a protein called TXNDC5. Think of TXNDC5 as a foreman working inside the endothelial cells (the inner lining of the blood vessels).

• In a healthy city: The foreman does just enough work to keep the roads smooth.
• In PH: The foreman goes into overdrive. He starts shouting orders to build too much "concrete" and "steel" (extracellular matrix) around the roads. This extra material makes the roads thick, stiff, and narrow.

The Discovery:
The team found that in patients with PH, this foreman (TXNDC5) is working 3.5 times harder than normal. When they removed this foreman in mice, the "traffic jam" didn't happen, and the heart stayed healthy. When they forced the foreman to work even harder, the disease got worse.

---

The Chain Reaction: How the Foreman Gets the Job

How does this foreman get so crazy? The paper reveals a three-step chain reaction:

1. The Alarm (Hypoxia): When the lungs don't get enough oxygen (hypoxia), a "alarm signal" called HIF-2α turns on.
2. The Order (TXNDC5): This alarm tells the TXNDC5 foreman, "Start building!"
3. The Material (BGN): The foreman then grabs a specific type of construction material called Biglycan (BGN).

The Analogy:
Imagine HIF-2α is the city mayor screaming, "Build a wall!"
TXNDC5 is the foreman who hears the mayor and starts the machinery.
BGN is the bricks being laid down.

The researchers found that TXNDC5 is essential for "folding" the bricks (BGN) correctly so they can be used. If the foreman (TXNDC5) is missing, the bricks (BGN) are crumpled and useless, so the wall never gets built, and the roads stay open.

---

The Solution: Stopping the Construction

The researchers tested two ways to stop this runaway construction project:

1. The Chemical Brake (E64FC26): They used a drug that acts like a gag order for the foreman. It stops TXNDC5 from working. In rats with PH, this drug cleared the roads, lowered the pressure, and saved the heart.
2. The Gene Therapy (Silencing): They used a virus (a delivery truck) to drop a "silence button" specifically into the lung cells. This turned off the TXNDC5 gene. The result was the same: the roads stayed open, and the heart was protected.

Why This Matters

This study is a breakthrough for three reasons:

1. It finds the root cause: It shows that the problem starts with the lining of the blood vessels (endothelial cells), not just the muscle around them.
2. It identifies a new target: Instead of just trying to relax the muscles (current treatments), we can stop the "construction" at the source by targeting TXNDC5.
3. It offers a biomarker: The researchers found that the "bricks" (BGN) spill out into the blood. They found that patients with severe PH have high levels of BGN in their blood. This means a simple blood test could tell doctors how bad the "construction" is and how well a treatment is working.

The Bottom Line

Think of Pulmonary Hypertension as a city where a specific foreman (TXNDC5) is mistakenly ordering too much construction, turning smooth roads into concrete walls. This paper proves that if you fire that foreman or stop him from folding the bricks (BGN), you can stop the city from collapsing. This opens the door for new drugs that could actually reverse the disease, not just manage it.

Technical Summary

1. Problem Statement

Pulmonary Hypertension (PH) is a fatal cardiovascular disease characterized by elevated pulmonary artery pressure, vascular remodeling, and right heart failure. Current treatments are largely palliative and cannot reverse established vascular remodeling. The pathogenesis involves endothelial dysfunction, smooth muscle proliferation, and, critically, extracellular matrix (ECM) remodeling, which often precedes vascular thickening. The specific molecular mechanisms driving ECM dysregulation in PH, particularly the role of protein folding enzymes in endothelial cells (ECs), remain poorly understood. There is an urgent need to identify novel therapeutic targets that address the root causes of ECM homeostasis failure.

2. Methodology

The study employed a multi-disciplinary approach combining human clinical data, animal models, and molecular biology techniques:

• Proteomics & Transcriptomics:
  • 4D Label-free Proteomics: Performed on lung tissues from 5 PH patients and 5 non-PH donors to identify dysregulated Protein Disulfide Isomerase (PDI) family members.
  • Single-cell RNA Sequencing (scRNA-seq): Analyzed lung tissues from Sugen5416/hypoxia (SuHx) rat models to identify cell subpopulations and transcriptional states.
  • Bulk RNA-seq: Conducted on pulmonary artery endothelial cells (PAECs) with TXNDC5 silencing to map downstream gene networks.
• Animal Models:
  • SuHx Model: A severe rat/mouse model of PH induced by VEGF receptor blockade (Su5416) followed by chronic hypoxia.
  • Genetic Manipulation: Utilized global TXNDC5 knockout mice ($TXNDC5^{-/-}$), endothelial-specific TXNDC5 knockout mice ($TXNDC5^{ECKO}$), and endothelial-specific BGN knockout mice ($BGN^{ECKO}$).
  • Gain-of-Function: Used Adeno-associated viruses (AAV) to overexpress TXNDC5 or HIF-2α specifically in lung ECs.
• Molecular & Cellular Assays:
  • Mechanistic Studies: Chromatin Immunoprecipitation (ChIP), dual-luciferase reporter assays, and molecular docking to study HIF-2α binding and TXNDC5-BGN interaction.
  • Protein Folding: Fluorescence Resonance Energy Transfer (FRET) assays and Cycloheximide (CHX) chase assays to assess BGN folding and stability.
  • Therapeutic Intervention: Tested the PDI inhibitor E64FC26 and endothelium-targeted shRNA gene therapy (scAAV-shTXN) in PH rats.
• Clinical Correlation: Measured serum Biglycan (BGN) levels in PH patients and correlated them with hemodynamic parameters.

3. Key Contributions

• Identification of TXNDC5: Discovered Thioredoxin Domain Containing 5 (TXNDC5), an endothelial-specific PDI, as a critical driver of PH pathogenesis.
• Elucidation of the HIF-2α/TXNDC5 Axis: Established that Hypoxia-Inducible Factor-2α (HIF-2α) transcriptionally activates TXNDC5, linking hypoxic signaling to pathological ECM remodeling.
• Discovery of a Novel Cell Subpopulation: Identified a distinct $TXNDC5^{high}$ ECM-producing endothelial cell subpopulation in PH lungs that drives matrix deposition.
• Mechanism of Action: Defined the molecular mechanism where TXNDC5 acts as a chaperone to facilitate the folding and stability of Biglycan (BGN), a key ECM proteoglycan.
• Therapeutic Validation: Demonstrated that both pharmacological inhibition (E64FC26) and gene therapy targeting endothelial TXNDC5 effectively reverse PH in preclinical models.

4. Key Results

A. TXNDC5 is Upregulated in PH and Drives Remodeling

• Proteomics revealed TXNDC5 as the most significantly upregulated PDI family member in PH patient lungs (3.45-fold increase).
• In SuHx models, TXNDC5 was predominantly localized in endothelial cells of remodeled distal pulmonary arteries.
• Loss-of-Function: Global or endothelial-specific deletion of TXNDC5 significantly attenuated right ventricular systolic pressure (RVSP), reduced right ventricular hypertrophy, and prevented pulmonary arterial muscularization.
• Gain-of-Function: Endothelial-specific overexpression of TXNDC5 exacerbated PH severity, increasing RVSP and vascular wall thickness.

B. The HIF-2α/TXNDC5 Transcriptional Axis

• HIF-2α activity was elevated in PH endothelial cells.
• HIF-2α directly binds to two specific sites (BS1 and BS2) in the TXNDC5 promoter, driving its transcription.
• Overexpression of a stabilized HIF-2α mutant induced mild PH phenotypes in wild-type mice, but this effect was abolished in $TXNDC5^{ECKO}$ mice, proving TXNDC5 is a necessary downstream mediator of HIF-2α.

C. TXNDC5 Regulates ECM via Biglycan (BGN)

• scRNA-seq identified a specific EC cluster ($TXNDC5^{high}$) enriched for ECM genes, including BGN.
• TXNDC5 physically interacts with BGN. Molecular docking and mutagenesis (C89A, G351A) confirmed that TXNDC5's PDI active sites are essential for this binding.
• Folding Mechanism: TXNDC5 facilitates the correct disulfide bond formation and folding of BGN. Inhibition of TXNDC5's PDI activity or silencing TXNDC5 leads to BGN degradation and reduced secretion.
• Downstream Effect: Endothelial-specific deletion of BGN ($BGN^{ECKO}$) mimicked the protective effects of TXNDC5 deletion, confirming BGN as the critical effector.

D. Therapeutic Efficacy

• Pharmacological Inhibition: Treatment with the PDI inhibitor E64FC26 significantly reduced RVSP, reversed vascular remodeling, and improved right heart function in SuHx rats. Crucially, E64FC26 lost efficacy in $TXNDC5^{ECKO}$ mice, confirming its mechanism is TXNDC5-dependent.
• Gene Therapy: Endothelium-targeted scAAV delivery of shRNA against TXNDC5 (shTXN) effectively silenced the gene in the lungs and ameliorated PH severity.
• Biomarker Potential: Serum BGN levels were significantly elevated in PH patients and correlated strongly with mean pulmonary artery pressure (mPAP) and systolic pulmonary artery pressure (sPAP), suggesting BGN as a diagnostic biomarker.

5. Significance

This study provides a comprehensive mechanistic link between hypoxia, endothelial dysfunction, and extracellular matrix remodeling in Pulmonary Hypertension.

1. Novel Pathway: It defines the HIF-2α $\rightarrow$ TXNDC5 $\rightarrow$ BGN axis as a central driver of PH, moving beyond simple proliferation models to focus on protein folding and ECM homeostasis.
2. Therapeutic Target: TXNDC5 is validated as a promising, druggable target. The study demonstrates that inhibiting TXNDC5 (either chemically or genetically) can reverse established disease phenotypes in preclinical models.
3. Clinical Translation: The identification of serum BGN as a biomarker offers a potential tool for non-invasive diagnosis and monitoring of disease severity.
4. Precision Medicine: The findings highlight the importance of targeting endothelial-specific mechanisms, as global PDI inhibition might have off-target effects, whereas endothelial-targeted strategies (like the scAAV approach) show high specificity and efficacy.

In conclusion, the paper establishes TXNDC5 as a master regulator of ECM homeostasis in PH, offering a new paradigm for developing curative therapies that target the structural integrity of the pulmonary vasculature.